Guy Nohra is a co-founder of Alta Partners, and was also a partner at Burr, Egan, Deleage & Co., which he joined in 1989. Nohra has been involved in the funding and development of notable medical technology and life science companies including ATS Medical, Cutera, Innerdyne, R2 Technology, deCODE genetics, and Vesica.
Previously, Nohra was Product Manager of Medical Products with Security Pacific Trading Corporation. He was responsible for a multi-million dollar product line and traveled extensively in Korea, Taiwan, Hong Kong, China and Southeast Asia.
Currently, Nohra serves on the board of directors of several companies, including AcelRx Pharmaceuticals, Carbylan Biosurgery, PneumRx and Vertiflex, and is the Chairman of the Board of USGI Medical. He also serves on the board of directors of the Medical Device Manufacturing Association (MDMA). He was recently named to the Forbes “Midas List” of dealmakers in high-tech and life sciences. Nohra also serves as the President of the Silicon Valley chapter of The Leukemia and Lymphoma Society.
He holds a Master of Business Administration from the University of Chicago and a Bachelor of Arts in History from Stanford University.
What is Guy P. Nohra's net worth?
The estimated net worth of Guy P. Nohra is at least $1.01 million as of December 4th, 2025. Nohra owns 116,610 shares of Bioventus stock worth more than $1,005,178 as of March 13th. This net worth approximation does not reflect any other assets that Nohra may own. Learn More about Guy P. Nohra's net worth.
How do I contact Guy P. Nohra?
Has Guy P. Nohra been buying or selling shares of Bioventus?
Guy P. Nohra has not been actively trading shares of Bioventus during the last quarter. Most recently, Guy P. Nohra sold 10,000 shares of the business's stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $7.57, for a transaction totalling $75,700.00. Following the completion of the sale, the director now directly owns 116,610 shares of the company's stock, valued at $882,737.70. Learn More on Guy P. Nohra's trading history.
Who are Bioventus' active insiders?
Are insiders buying or selling shares of Bioventus?
During the last twelve months, insiders at the sold shares 7 times. They sold a total of 53,031 shares worth more than $427,812.14. The most recent insider tranaction occured on March, 11th when Director Michelle Mcmurry-Heath sold 12,000 shares worth more than $105,480.00. Insiders at Bioventus own 33.0% of the company.
Learn More about insider trades at Bioventus. Information on this page was last updated on 3/11/2026.
